<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2020-12-46-53</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-5864</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЗАБОЛЕВАНИЯ КОЖИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>DERMAL DISEASES</subject></subj-group></article-categories><title-group><article-title>Путь пациента к атопическому дерматиту: исследование приверженности пациентов к терапии</article-title><trans-title-group xml:lang="en"><trans-title>The patient's path to AD: a study of patients adherence to therapy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5044-5265</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Круглова</surname><given-names>Л. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kruglova</surname><given-names>L. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Круглова Лариса Сергеевна – доктор медицинских наук, профессор, проректор по учебной работе, заведующая кафедрой дерматовенерологии и косметологии.121359, Москва, ул. Маршала Тимошенко, д. 19, стр. 1а.</p></bio><bio xml:lang="en"><p>Larisa S. Kruglova - Dr. of Sci. (Med.), Professor, Vice-rector for academic Affairs, Head of the Department of dermatovenerology and cosmetology, Central State Medical Academy of the Presidential administration of the Russian Federation.19, Bldg. 1а, Marshal Timoshenko St., Moscow, 121359.</p></bio><email xlink:type="simple">kruglovals@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3437-5233</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Грязева</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Griazeva</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Грязева Наталья Владимировна - кандидат медицинских наук, доцент кафедры дерматовенерологии и косметологии.121359, Москва, ул. Маршала Тимошенко, д. 19, стр. 1а.</p></bio><bio xml:lang="en"><p>Natalia V. Gryazeva - Cand. of Sci. (Med.), associate Professor of the Department of dermatovenerology and cosmetology, Central State Medical Academy of the Presidential administration of the Russian Federation.19, Bldg. 1а, Marshal Timoshenko St., Moscow, 121359.</p></bio><email xlink:type="simple">tynrik@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Центральная государственная медицинская академия</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Central State Medical Academy</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>14</day><month>11</month><year>2020</year></pub-date><volume>0</volume><issue>12</issue><fpage>46</fpage><lpage>53</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Круглова Л.С., Грязева Н.В., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Круглова Л.С., Грязева Н.В.</copyright-holder><copyright-holder xml:lang="en">Kruglova L.S., Griazeva N.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/5864">https://www.med-sovet.pro/jour/article/view/5864</self-uri><abstract><sec><title>Введение</title><p>Введение. Атопический дерматит является одним из наиболее распространенных заболеваний кожи. Распространенность атопического дерматита среди детского населения составляет до 20%, среди взрослого населения - 2-8%. В течение последних десятилетий наблюдается рост заболеваемости АД, усложняется его течение, отягощается исход. В связи с этим поиск новых успешных методов лечения, а также детальный анализ используемых в настоящее время схем лечения является актуальной задачей.Цель. Измерить распределение пациентов с АД по формам течения (легкая, среднетяжелая, тяжелая) с описанием пути пациента, включая наиболее важные моменты принятия решений, драйверы переключений, изменений в терапии, основные группы влияния, выявить основные информационные запросы/нужды пациентов с АД.Материалы и методы. В исследовании приняло участие 700 пациентов, включая 96 пациентов со среднетяжелой формой и 116 с тяжелой формой. У всех пациентов был диагностирован АД, пациенты имели как минимум одно обострение за последний год. Возраст пациентов составил 18-60 лет.Результаты. Получены данные, что пациенты со среднетяжелой и тяжелой формой АД составляют около 25% всех пациентов с АД, из них пациенты с тяжелой формой - около 5%. Антигистаминные препараты наиболее часто используются пациентами с АД, и препарат именно этой категории пациенты чаще всего называют «основным» препаратом от АД. Пациенты с тяжелой формой АД значительно чаще других групп используют стероиды и иммуносупрессанты. Рекомендация врача (дерматолога в муниципальной клинике или КВД) является наиболее значимым фактором, обуславливающим выбор препарата для лечения атопического дерматита.</p></sec><sec><title>Выводы</title><p>Выводы. По нашему мнению, необходимо повышать информированность населения об особенностях образа жизни при АД, теоретических аспектах лечения и уходе за кожей, например проводить с пациентами специальные образовательные мероприятия по типу «школ атопического дерматита».</p></sec></abstract><trans-abstract xml:lang="en"><p>Introduction. Atopic dermatitis (AD) is one of the most common skin diseases. The prevalence of atopic dermatitis among children is up to 20%, among adults - 2-8%. According to the form, there are mild, moderate and severe AD. Over the past decades, there has been an increase in the incidence of AD, its course is becoming more complicated, and the outcome is becoming more difficult. In this regard, the search for new successful treatment methods, as well as a detailed analysis of the currently used treatment regimens, is an urgent task. Goal. Measure the distribution of patients with AD by type of course (mild, moderate, severe) with a description of the patient's path, including the most important moments of decision-making, drivers of switching, changes in therapy, the main groups of influence and identify the main information requests/needs of patients with AD.Materials and methods. The study involved 700 patients, including 96 patients with moderate to severe form and 116 with severe form. All patients were diagnosed with AD and had at least one exacerbation in the last year. The age of the patients was 18-60 years. Results. The data obtained show that patients with moderate to severe AD make up about 25% of all patients with AD, including patients with severe ad - about 5%. Antihistamines are most often used by patients with AD, and the drug in this category is most often referred to by patients as the “main” drug for AD. More than half of patients (60%) with moderate to severe AD have used systemic steroids and/or cyclosporins over the past year. Patients with severe AD are significantly more likely than other groups to use steroids and immunosuppressants. The recommendation of a doctor (most often - a dermatologist in a municipal clinic or a skin and venereal clinic) is the most significant factor determining the choice of a drug for the treatment of atopic dermatitis. Conclusions. The data obtained indicate the need to conduct special educational activities with patients such as “schools of atopic dermatitis”, informing patients about the features of lifestyle in AD, theoretical aspects of treatment and skin care.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>атопический дерматит</kwd><kwd>формы течения</kwd><kwd>пациенты</kwd><kwd>терапия</kwd><kwd>выбор препарата</kwd></kwd-group><kwd-group xml:lang="en"><kwd>atopic dermatitis</kwd><kwd>forms</kwd><kwd>patients</kwd><kwd>therapy</kwd><kwd>drug selection</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Drucker A.M., Wang A.R., Li W.Q., Sevetson E., Block J.K., Qureshi A.A. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30. doi: 10.1016/j.jid.2016.07.012.</mixed-citation><mixed-citation xml:lang="en">Drucker A.M., Wang A.R., Li W.Q., Sevetson E., Block J.K., Qureshi A.A. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30. doi: 10.1016/j.jid.2016.07.012.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Wollenberg A., Barbarot S., Bieber T., Christen-Zaech S., Deleuran M., Fink-Wagner A. et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657-682. doi: 10.1111/jdv.14891.</mixed-citation><mixed-citation xml:lang="en">Wollenberg A., Barbarot S., Bieber T., Christen-Zaech S., Deleuran M., Fink-Wagner A. et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657-682. doi: 10.1111/jdv.14891.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Кубанов А.А., Богданова Е.В. Организация и результаты оказания медицинской помощи по профилю «дерматовенерология» в Российской Федерации. Итоги 2018 года. Вестник дерматологии и венерологии. 2019;95(4):8-23. doi: 10.25208/0042-4609-2019-95-4-8-23.</mixed-citation><mixed-citation xml:lang="en">Kubanov A.A., Bogdanova E.V. Dermatovenereologic health care delivery management in the Russian Federation. Results of 2018. Vestnik dermatologii i venereologii = Bulletin of Dermatology and Venereology. 2019;95(4):8-23. (In Russ.) doi: 10.25208/0042-4609-2019-95-4-8-23.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Williams H.C., Strachan D.P. The natural history of childhood eczema: observations from the British 1958 birth cohort study. Br J Dermatol. 1998;139(5):834-839. doi: 10.1046/j.1365-2133.1998.02509.x.</mixed-citation><mixed-citation xml:lang="en">Williams H.C., Strachan D.P. The natural history of childhood eczema: observations from the British 1958 birth cohort study. Br J Dermatol. 1998;139(5):834-839. doi: 10.1046/j.1365-2133.1998.02509.x.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ozkaya E. Adult-onset atopic dermatitis. J Am Acad Dermatol. 2005;52(4):579-582. doi: 10.1016/j.jaad.2004.11.037.</mixed-citation><mixed-citation xml:lang="en">Ozkaya E. Adult-onset atopic dermatitis. J Am Acad Dermatol. 2005;52(4):579-582. doi: 10.1016/j.jaad.2004.11.037.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ellis C.N., Mancini A.J., Paller A.S., Simpson E.L., Eichenfield L.F. Understanding and managing atopic dermatitis in adult patients. Semin Cutan Med Surg. 2012;31(3S):18-22. doi: 10.1016/j.sder.2012.07.006.</mixed-citation><mixed-citation xml:lang="en">Ellis C.N., Mancini A.J., Paller A.S., Simpson E.L., Eichenfield L.F. Understanding and managing atopic dermatitis in adult patients. Semin Cutan Med Surg. 2012;31(3S):18-22. doi: 10.1016/j.sder.2012.07.006.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ring J., Alomar A., Bieber T., Deleuran M., Fink-Wagner A., Gelmetti C. et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermat ol Venereol. 2012;26(8):1045-1060. doi: 10.1111/j.1468-3083.2012.04635.x.</mixed-citation><mixed-citation xml:lang="en">Ring J., Alomar A., Bieber T., Deleuran M., Fink-Wagner A., Gelmetti C. et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermat ol Venereol. 2012;26(8):1045-1060. doi: 10.1111/j.1468-3083.2012.04635.x.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Malajian D., Guttman-Yassky E. New pathogenic and therapeutic paradigms in atopic dermatitis. Cytokine. 2015;73(2):311-318. doi: 10.1016/j.cyto.2014.11.023.</mixed-citation><mixed-citation xml:lang="en">Malajian D., Guttman-Yassky E. New pathogenic and therapeutic paradigms in atopic dermatitis. Cytokine. 2015;73(2):311-318. doi: 10.1016/j.cyto.2014.11.023.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ricci G., Patrizi A., Bellini F., Medri M. Use of textiles in atopic dermatitis: care of atopic dermatitis. Curr Probl Dermatol. 2006;33:127-143. doi: 10.1159/000093940.</mixed-citation><mixed-citation xml:lang="en">Ricci G., Patrizi A., Bellini F., Medri M. Use of textiles in atopic dermatitis: care of atopic dermatitis. Curr Probl Dermatol. 2006;33:127-143. doi: 10.1159/000093940.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
